AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)

AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion. https://www.nasdaq.com/articles/astrazenecas-enhertu-wins-eu-nod-her2-positive-solid-tumors-revised